pharma news today obesity drugs glp-1 october 2025 Market The GLP-1 Revolution Continues

National Taiwan University researchers highlight the benefits of GLP-1 receptor agonists (GLP-1 RAs) in reducing mortality and severe cardiovascular and renal outcomes for diabetic patients with acute kidney disease (AKD)

Tarun: +91 9891 296 838 | Mr

planned combo with YP05002 a unique differentiator vs Lilly and Novo

Navigate the challenges of GLP-1 medications and constipation on your weight loss journey with expert insights from LifeRx.md, Inc

2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.

Non-candidates and other refund requests will be honored before service provided